Navigation Links
SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
Date:5/4/2009

CALGARY, May 4 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture of high-value proteins and oils in plant seeds, today announced that it has reached an agreement with AVAC Ltd. for a $1.5 million loan for the development of its Apo AIMilano candidate. AVAC is a private, not-for-profit company that invests in research initiatives and early stage commercial businesses that expand Alberta's value-added industry.

The funds will be advanced with an upfront payment followed by two smaller installments based on the execution of short term Apo AIMilano development milestones expected to be completed by January 2010. The funds are repayable at the end of 18 months with interest.

"This funding comes at a very important time as it will contribute towards the achievement of near-term objectives for our Apo AIMilano candidate and allow us to leverage additional funding opportunities," said James Szarko, President and CEO of SemBioSys Genetics Inc. "AVAC's continued support reflects the shared vision of our enabling technology platform and its applicability to biopharmaceuticals like Apo AIMilano. This next-generation drug has the potential to meet a very large unmet need in cardiovascular disease. The terms of the funding provide us sufficient time to execute substantial value-generating milestones for this promising program."

"AVAC has very high hopes for SemBioSys' technology platform and has been a strong supporter of the Company since 2001. The Apo AIMilano product has true blockbuster potential and will provide the medical community with new tools to address the debilitating and potentially life-threatening consequences of atherosclerosis," says Jim Hardin, AVAC Investment Manager.

"In addition to its direct investments in early-stage companies, AVAC also participates in commercially-relevant agricultural research and we are the leading early-stage venture capital fund-of-fund investor in Alberta," said Ross Bricker, AVAC President and CEO. "Since 1997, with the support of the Alberta and Canadian Governments, we have invested in and provided guidance to over 110 early-stage companies who have reported more than $340 million in aggregate sales to date that can be directly attributed to AVAC investments."

About SemBioSys

Calgary, Alberta-based SemBioSys is a world leader in manufacturing high-value proteins and oils in plant seeds. With its unique, proprietary platform, SemBioSys provides partners with product enablement, exceptionally low cost and unprecedented scalability. The Company applies this platform with high selectivity to opportunities where it has a unique competitive advantage. Since its inception, SemBioSys has produced more than 50 non-native proteins and oils using its patented seed technology, demonstrating applicability across a broad range of industries such as pharmaceuticals, personal care and industrial products. The Company's current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AIMilano, a next-generation cardiovascular therapy. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions and market size, the acceptance of an IND by the FDA in respect of clinical studies, the submission of a CTA to the appropriate European authorities, the successful initiation and timely and successful completion of clinical studies, the fact that Apo AIMilano is currently a development stage drug, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.


'/>"/>
SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys provides update on insulin program
2. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
3. SemBioSys announces senior management changes
4. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
5. SemBioSys begins phase I/II trial of insulin produced in plant seeds
6. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
7. SemBioSys announces second quarter 2008 financial and operational results
8. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
9. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
10. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
11. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Palo Alto, CA (PRWEB) , ... September 20, ... ... and public interest organization focused on molecular manufacturing and other transformative technologies, announced ... categories, one for Experiment and the other for Theory in nanotechnology/molecular manufacturing. , ...
(Date:9/19/2017)... ... 19, 2017 , ... Participants of this educational webinar will ... Along with the advantages and disadvantages of ductless, filtered fume hoods, they will ... laboratory. , Attendees will learn from an industry expert about the different types ...
(Date:9/19/2017)... ... September 19, 2017 , ... The new and improved Oakton® pocket ... testers even stand upright with a new cap design that is versatile, functional and ... field who need to test water quality. , The Oakton pocket testers have many ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... is pleased to announce the recipients of its 2017 Science Student Award. The ... leadership qualities, and involvement with community service defray the costs of obtaining their ...
Breaking Biology Technology:
(Date:8/15/2017)... HAMPTON, Va. , Aug. 15 2017   ivWatch LLC ... effectiveness of intravenous (IV) therapy, today announced receipt of its ISO ... (QMS) developed by the International Organization for Standardization (ISO┬«). ... ivWatch Model 400 Continuous Monitoring device for ... "This ...
(Date:5/23/2017)... 2017  Hunova, the first robotic gym for the rehabilitation and functional ... in Genoa, Italy . The first 30 robots will ... USA . The technology was developed and patented at ... IIT spin-off Movendo Technology thanks to a 10 million euro investment from ... click: ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):